Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.
Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Focused rotary jet spinning appears to hold some key advantages over 3D printing and other techniques. Engineers at Harvard think it could represent the future of organ biofabrication.
The study's authors noted that the ECG acquisition technology in these wearable devices appears to be quite effective. The automated algorithms, however, could still be improved.
The four-year analysis will use cardiac MRI scans to closely monitor the heart health of people living with HIV who regularly use cannabis to treat their symptoms.
The study, published in the American Journal of Cardiology, included data from more than 900 TAVR patients. Overall morality was 22.7% among patients with AFib and 14.4% among patients without AFib.
The new guideline calls for a “stepwise approach," followed by close clinical surveillance, when treating uncomplicated TBAD. In some cases, however, earlier endovascular treatments may be necessary.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
